New Agreements Signed Between Lexaria Bioscience Corp. (NASDAQ: LEXX) and BevNology LLC; Pre-IND Meeting Request Filed with FDA
The two companies signed a manufacturing operating agreement and a commercial agreement Lexaria sent a pre-IND meeting request letter to the US FDA and plans to file the full IND application in late 2022/early 2023The FDA has acknowledged Lexaria's pre-IND request and responded with conditions prior to the target date of July 30, 2022 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has…